Treatment Use Study for Advanced Melanoma.
Study Details
Study Description
Brief Summary
The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
This is an expanded access trial that canceled prior to enrolling patients.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Advanced melanoma with life expectancy of at least 6 months.
-
Melanoma must be considered unresectable.
-
Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month.
Exclusion Criteria:
-
Patients must not be eligible for participation in any ongoing CP-675,206 clinical studies currently open for enrollment.
-
History of chronic inflammatory or autoimmune disease.
-
History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- A3671028